Overview

A Study Evaluating Atezolizumab, With or Without Bevacizumab, in Patients With Unresectable Hepatocellular Carcinoma and Child-Pugh B7 and B8 Cirrhosis

Status:
Recruiting

Trial end date:
2026-11-16

Target enrollment:

Participant gender:

Summary

The purpose of this study is to assess the safety and efficacy of atezolizumab and bevacizumab, or atezolizumab alone, as first-line treatment in participants with unresectable, locally advanced or metastatic hepatocellular carcinoma (HCC) with Child-Pugh B7 or B8 cirrhosis.

Phase:

Phase 2

Details

Lead Sponsor:

Genentech, Inc.

Treatments:

Atezolizumab
Bevacizumab